Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

Akeso received clinical trial clearance from China’s CDE for its next-generation B7-H3-targeting antibody-drug conjugate (ADC) AK157D1, clearing the way to advance the program into clinical study. The regulatory milestone is a constructive step for the pipeline but the article provides no efficacy or timeline details.

Analysis

Akeso received clinical trial clearance from China’s CDE for its next-generation B7-H3-targeting antibody-drug conjugate (ADC) AK157D1, clearing the way to advance the program into clinical study. The regulatory milestone is a constructive step for the pipeline but the article provides no efficacy or timeline details.